Results 61 to 70 of about 38,655 (210)

New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report

open access: yesSAGE Open Medical Case Reports
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster ...
Eman Badawod
doaj   +1 more source

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

open access: yesFrontiers in Medicine, 2022
BackgroundBullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal ...
Francesco Moro   +7 more
doaj   +1 more source

Buccal Mucosa as Substrate for Direct Immunofluorescence Should Be Included Early in the Diagnostic Work Up of Ocular Mucous Membrane Pemphigoid

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background In ocular mucous membrane pemphigoid (MMP) direct immunofluorescence (DIF) represents the gold standard for definitive diagnosis. However, up to 50% of ocular MMP cases do not meet the immunopathological criteria. In addition, the risk of exacerbating conjunctival cicatrization makes ocular biopsy technically difficult to obtain ...
Andrea Gabusi   +6 more
wiley   +1 more source

Case Report: Variety of Target Antigens During 1 Year Follow-Up of a Patient Initially Diagnosed With Bullous Pemphigoid

open access: yesFrontiers in Immunology, 2022
Autoimmune bullous diseases (AIBDs), presenting cutaneous and/or mucosal bullous lesions, are classified into pemphigus and pemphigoid diseases. A longtime observation for complicated AIBD cases is rarely reported.
Hua Qian   +9 more
doaj   +1 more source

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga   +6 more
wiley   +1 more source

Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine

open access: yesDiagnostics
Background: Bullous pemphigoid is an autoimmune bullous disease that frequently affects a large skin surface area, but it can also present in localized areas.
Emi Mashima   +2 more
doaj   +1 more source

Pemphigoid vegetans in childhood: A case report and short review of literature

open access: yesIndian Journal of Dermatology, 2015
Pemphigoid vegetans is a very rare type of bullous pemphigoid which usually affects the elderly and has not been reported in children. It shows a clinical resemblance to pemphigus vegetans but has distinct histological and immunopathological features of ...
Yasmeen Khatib   +3 more
doaj   +1 more source

Metronidazole-Induced Bullous Pemphigoid: A Case Report [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2015
Bullous pemphigoid is an autoimmune cutaneous blistering disorder, the exact pathogenesis of which is still not fully elucidated. Drug-induced bullous pemphigoid eruptions are rare but have been reported earlier with the use of frusemide, psoralens ...
Saibal Moitra   +4 more
doaj   +1 more source

Bullous Pemphigoid: Trigger and Predisposing Factors

open access: yesBiomolecules, 2020
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230.
F. Moro   +4 more
semanticscholar   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy